JPS58103319A - 皮膚塗布用組成物 - Google Patents
皮膚塗布用組成物Info
- Publication number
- JPS58103319A JPS58103319A JP20008581A JP20008581A JPS58103319A JP S58103319 A JPS58103319 A JP S58103319A JP 20008581 A JP20008581 A JP 20008581A JP 20008581 A JP20008581 A JP 20008581A JP S58103319 A JPS58103319 A JP S58103319A
- Authority
- JP
- Japan
- Prior art keywords
- skin
- composition
- acid
- dicarboxylic acid
- ethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 47
- 206010000496 acne Diseases 0.000 claims abstract description 23
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims abstract description 19
- 208000003351 Melanosis Diseases 0.000 claims abstract description 12
- -1 dicarboxylic acid ester Chemical class 0.000 claims abstract description 7
- 208000002874 Acne Vulgaris Diseases 0.000 claims description 20
- 239000004480 active ingredient Substances 0.000 claims description 13
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 9
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 claims description 6
- 150000001875 compounds Chemical class 0.000 claims description 5
- 125000004432 carbon atom Chemical group C* 0.000 claims description 3
- 239000006187 pill Substances 0.000 claims 1
- 239000002253 acid Substances 0.000 abstract description 42
- 230000000694 effects Effects 0.000 abstract description 13
- 206010014970 Ephelides Diseases 0.000 abstract description 11
- 230000000144 pharmacologic effect Effects 0.000 abstract description 9
- 206010040880 Skin irritation Diseases 0.000 abstract description 6
- 230000036556 skin irritation Effects 0.000 abstract description 6
- 231100000475 skin irritation Toxicity 0.000 abstract description 6
- 208000024891 symptom Diseases 0.000 abstract description 6
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 abstract description 4
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 abstract description 4
- NQYXFXWKKYGBNL-UHFFFAOYSA-N 7-ethoxy-7-oxoheptanoic acid Chemical compound CCOC(=O)CCCCCC(O)=O NQYXFXWKKYGBNL-UHFFFAOYSA-N 0.000 abstract description 2
- 206010064127 Solar lentigo Diseases 0.000 abstract 1
- 230000002255 enzymatic effect Effects 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 description 16
- 238000009472 formulation Methods 0.000 description 13
- 239000002884 skin cream Substances 0.000 description 9
- 230000000052 comparative effect Effects 0.000 description 8
- 238000001816 cooling Methods 0.000 description 8
- 238000000034 method Methods 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 239000006071 cream Substances 0.000 description 6
- 239000002674 ointment Substances 0.000 description 6
- WLJVNTCWHIRURA-UHFFFAOYSA-M pimelate(1-) Chemical compound OC(=O)CCCCCC([O-])=O WLJVNTCWHIRURA-UHFFFAOYSA-M 0.000 description 6
- 229910019142 PO4 Inorganic materials 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 239000006210 lotion Substances 0.000 description 5
- BDJRBEYXGGNYIS-UHFFFAOYSA-N nonanedioic acid Chemical compound OC(=O)CCCCCCCC(O)=O BDJRBEYXGGNYIS-UHFFFAOYSA-N 0.000 description 5
- 235000021317 phosphate Nutrition 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 230000009471 action Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 239000002537 cosmetic Substances 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 238000006386 neutralization reaction Methods 0.000 description 4
- 239000010452 phosphate Substances 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- MTRYLAXNDGUFAK-UHFFFAOYSA-N 9-ethoxy-9-oxononanoic acid Chemical compound CCOC(=O)CCCCCCCC(O)=O MTRYLAXNDGUFAK-UHFFFAOYSA-N 0.000 description 3
- 241000700199 Cavia porcellus Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 230000001747 exhibiting effect Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
- 230000001603 reducing effect Effects 0.000 description 3
- PGBZISLWIREORZ-UHFFFAOYSA-N 9-oxo-9-propan-2-yloxynonanoic acid Chemical compound CC(C)OC(=O)CCCCCCCC(O)=O PGBZISLWIREORZ-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 208000001840 Dandruff Diseases 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 240000007594 Oryza sativa Species 0.000 description 2
- 235000007164 Oryza sativa Nutrition 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 208000006981 Skin Abnormalities Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- LKKOGZVQGQUVHF-UHFFFAOYSA-N diethyl heptanedioate Chemical compound CCOC(=O)CCCCCC(=O)OCC LKKOGZVQGQUVHF-UHFFFAOYSA-N 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- MCQNUBHLBYBDRS-UHFFFAOYSA-N dipropan-2-yl nonanedioate Chemical compound CC(C)OC(=O)CCCCCCCC(=O)OC(C)C MCQNUBHLBYBDRS-UHFFFAOYSA-N 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 239000000865 liniment Substances 0.000 description 2
- 229940040145 liniment Drugs 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 235000014593 oils and fats Nutrition 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 235000009566 rice Nutrition 0.000 description 2
- 238000011076 safety test Methods 0.000 description 2
- 239000012177 spermaceti Substances 0.000 description 2
- 229940084106 spermaceti Drugs 0.000 description 2
- 229940032094 squalane Drugs 0.000 description 2
- 238000013112 stability test Methods 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- YBADLXQNJCMBKR-UHFFFAOYSA-M (4-nitrophenyl)acetate Chemical compound [O-]C(=O)CC1=CC=C([N+]([O-])=O)C=C1 YBADLXQNJCMBKR-UHFFFAOYSA-M 0.000 description 1
- FFJCNSLCJOQHKM-CLFAGFIQSA-N (z)-1-[(z)-octadec-9-enoxy]octadec-9-ene Chemical compound CCCCCCCC\C=C/CCCCCCCCOCCCCCCCC\C=C/CCCCCCCC FFJCNSLCJOQHKM-CLFAGFIQSA-N 0.000 description 1
- ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 2,3-dimethylbutane Chemical group CC(C)C(C)C ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 0.000 description 1
- GHCZTIFQWKKGSB-UHFFFAOYSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;phosphoric acid Chemical compound OP(O)(O)=O.OC(=O)CC(O)(C(O)=O)CC(O)=O GHCZTIFQWKKGSB-UHFFFAOYSA-N 0.000 description 1
- BGRXBNZMPMGLQI-UHFFFAOYSA-N 2-octyldodecyl tetradecanoate Chemical compound CCCCCCCCCCCCCC(=O)OCC(CCCCCCCC)CCCCCCCCCC BGRXBNZMPMGLQI-UHFFFAOYSA-N 0.000 description 1
- SSZWWUDQMAHNAQ-UHFFFAOYSA-N 3-chloropropane-1,2-diol Chemical compound OCC(O)CCl SSZWWUDQMAHNAQ-UHFFFAOYSA-N 0.000 description 1
- SQJKDEQVXPFQGL-UHFFFAOYSA-N 4alpha-methylchlest-7-en-3beta-yl acetate Natural products CC1C(OC(C)=O)CCC2(C)C(CCC3(C(C(C)CCCC(C)C)CCC33)C)C3=CCC21 SQJKDEQVXPFQGL-UHFFFAOYSA-N 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical group CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 240000008620 Fagopyrum esculentum Species 0.000 description 1
- 235000009419 Fagopyrum esculentum Nutrition 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- WMFYOYKPJLRMJI-UHFFFAOYSA-N Lercanidipine hydrochloride Chemical compound Cl.COC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)(C)CN(C)CCC(C=2C=CC=CC=2)C=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 WMFYOYKPJLRMJI-UHFFFAOYSA-N 0.000 description 1
- 101001034845 Mus musculus Interferon-induced transmembrane protein 3 Proteins 0.000 description 1
- 235000004347 Perilla Nutrition 0.000 description 1
- 244000124853 Perilla frutescens Species 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 101150077854 USE1 gene Proteins 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000037374 absorbed through the skin Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 229940067597 azelate Drugs 0.000 description 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N beta-monoglyceryl stearate Natural products CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000004020 conductor Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 150000001990 dicarboxylic acid derivatives Chemical class 0.000 description 1
- CQMYCPZZIPXILQ-UHFFFAOYSA-N diethyl nonanedioate Chemical compound CCOC(=O)CCCCCCCC(=O)OCC CQMYCPZZIPXILQ-UHFFFAOYSA-N 0.000 description 1
- QFYNUCAKHMSPCY-UHFFFAOYSA-L disodium;nonanedioate Chemical compound [Na+].[Na+].[O-]C(=O)CCCCCCCC([O-])=O QFYNUCAKHMSPCY-UHFFFAOYSA-L 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 208000000069 hyperpigmentation Diseases 0.000 description 1
- 230000003810 hyperpigmentation Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- ZHLMUXSXJLAUEZ-UHFFFAOYSA-N nonanedioic acid phosphoric acid Chemical compound C(CCCCCCCC(=O)O)(=O)O.P(=O)(O)(O)O ZHLMUXSXJLAUEZ-UHFFFAOYSA-N 0.000 description 1
- 229940073665 octyldodecyl myristate Drugs 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/37—Esters of carboxylic acids
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Cosmetics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP20008581A JPS58103319A (ja) | 1981-12-14 | 1981-12-14 | 皮膚塗布用組成物 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP20008581A JPS58103319A (ja) | 1981-12-14 | 1981-12-14 | 皮膚塗布用組成物 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP4060183A Division JPS58170713A (ja) | 1983-03-14 | 1983-03-14 | 皮膚塗布用組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS58103319A true JPS58103319A (ja) | 1983-06-20 |
| JPH0323525B2 JPH0323525B2 (enrdf_load_stackoverflow) | 1991-03-29 |
Family
ID=16418599
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP20008581A Granted JPS58103319A (ja) | 1981-12-14 | 1981-12-14 | 皮膚塗布用組成物 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS58103319A (enrdf_load_stackoverflow) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS59106411A (ja) * | 1982-12-10 | 1984-06-20 | Kanebo Ltd | 美白化粧料 |
| JPS6456622A (en) * | 1987-08-28 | 1989-03-03 | Ss Pharmaceutical Co | Percutaneous absorbefacient base composition |
| JPH06298643A (ja) * | 1987-07-02 | 1994-10-25 | Carl R Thornfeldt | 皺の治療剤 |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013170158A (ja) * | 2012-02-22 | 2013-09-02 | Kao Corp | 経口紫外線抵抗性向上剤 |
-
1981
- 1981-12-14 JP JP20008581A patent/JPS58103319A/ja active Granted
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS59106411A (ja) * | 1982-12-10 | 1984-06-20 | Kanebo Ltd | 美白化粧料 |
| JPH06298643A (ja) * | 1987-07-02 | 1994-10-25 | Carl R Thornfeldt | 皺の治療剤 |
| JPS6456622A (en) * | 1987-08-28 | 1989-03-03 | Ss Pharmaceutical Co | Percutaneous absorbefacient base composition |
Also Published As
| Publication number | Publication date |
|---|---|
| JPH0323525B2 (enrdf_load_stackoverflow) | 1991-03-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8679552B2 (en) | Acne vulgaris treatment regimen | |
| US6911211B2 (en) | Pharmaceutical and cosmetic carrier or composition for topical application | |
| US8512718B2 (en) | Pharmaceutical composition for topical application | |
| US5633284A (en) | Nitrous oxide containing dermatological composition | |
| US4593046A (en) | Method of reducing skin irritation from benzoyl peroxide | |
| JPH08208488A (ja) | 皮膚外用剤 | |
| CN108066209A (zh) | 一种美白祛斑霜及其制备方法 | |
| JPS58103319A (ja) | 皮膚塗布用組成物 | |
| JPH06199688A (ja) | 面皰治療剤組成物 | |
| JPH0217115A (ja) | 美白化粧料 | |
| US6730703B2 (en) | Dual inhibitors of cholesteryl ester and wax ester synthesis for sebaceous gland disorders | |
| US20190321427A1 (en) | Compositions to Treat Anal Fissures | |
| US3825563A (en) | Production of stable,nonhydrous,homogeneous,in natural and mineral oils soluble vitamin-e-active cream-base-co-esters of the mineral-oil-insoluble d-alpha-tocopheryl-acid-succinate with anhydrous oils | |
| AU701833B2 (en) | Psoriasis treatment | |
| JPS6322510A (ja) | 皮膚外用剤 | |
| US10517821B1 (en) | Topical composition for pain relief | |
| JPS63183518A (ja) | 毛髪用組成物 | |
| KR100502069B1 (ko) | 홍삼 조사포닌을 함유하는 여드름 개선용 부직포 팩 | |
| JPH02221213A (ja) | 皮膚化粧料 | |
| JP2002332237A (ja) | 皮膚外用剤 | |
| JPS6327425A (ja) | 尋常性▲ざ▼瘡治療薬 | |
| JPS58170713A (ja) | 皮膚塗布用組成物 | |
| KR960015725B1 (ko) | 모발처리용 조성물 | |
| CN111686131A (zh) | 一种肛裂蛋黄霜及其制备方法 | |
| JPS6322509A (ja) | 外用剤 |